Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation

O. Tatar, K. Shinoda, E. Kaiserling, C. Claes, C. Eckardt, T. Eckert, G. Pertile, V. Boeyden, G. B. Scharioth, E. Yoeruek, P. Szurman, K. U. Bartz-Schmidt, S. Grisanti*

*Corresponding author for this work
    4 Citations (Scopus)


    Aim: To evaluate the implications of intravitreal bevacizumab on proangiogenic vascular endothelial growth factor (VEGF) with regard to the endogenous angiogenesis inhibitor endostatin in human choroidal neovascularisation (CNV) secondary to age-related macular degeneration. Methods: Retrospective review of an interventional case series of 48 patients who underwent full macular translocation surgery with removal of CNV. Twenty-five patients were treated with intravitreal bevacizumab injection 1 to 154 days prior to surgery (bevacizumab CNV). Twenty-three CNV without any kind of previous treatment were used as controls (control CNV). CNV were stained for CD34, cytokeratin18, VEGF, endostatin and Eselectin. A "predominance score of VEGF over endostatin" (PS) was defined by the difference between VEGF and endostatin staining scores. Results: Bevacizumab CNV revealed a weaker VEGF expression in endothelial cells (p = 0.0245) but significantly more intense endostatin in retina pigment epithelium (RPE) (p = 0.0001) and stroma (p<0.0001). Consequently, PS was significantly lower in RPE (p = 0.02), vessels (p = 0.03) and stroma (p = 0.0004) in bevacizumab CNV. The intensity of E-selectin expression in bevacizumab CNV was comparable with that in control CNV. Conclusions: A shift within the angiogenic balance in terms of decreased VEGF predominance over endostatin is detected in human CNV treated with bevacizumab.

    Translated title of the contributionAuswirkungen von Bevacizumab auf den vaskulären endothelialen Wachstumsfaktor und Endostatin bei der humanen choroidalen Neovaskularisation
    Original languageEnglish
    JournalBritish Journal of Ophthalmology
    Issue number2
    Pages (from-to)159-165
    Number of pages7
    Publication statusPublished - 01.02.2009


    Dive into the research topics of 'Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation'. Together they form a unique fingerprint.

    Cite this